Payment overview · 2025
General Payments
$1,526.82
80 reported records · 24 companies
Healthcare provider profile · identity verified
William T Korman, MD
Allopathic & Osteopathic Physicians|Family Medicine · LEXINGTON, SC · NPI 1740298066
Verified facts
What the public records show
CMS Open Payments records show William T Korman, MD received $1,526.82 in general payments during 2025 across 80 reported records.
AstraZeneca Pharmaceuticals LP accounted for 13.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 40 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Farxiga, Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Arexvy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $206.15 | 13.5% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $186.16 | 12.2% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $183.90 | 12.0% | 12 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $135.17 | 8.8% | 8 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $83.53 | 5.5% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $83.52 | 5.5% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $58.03 | 3.8% | 4 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $56.72 | 3.7% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $55.62 | 3.6% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $51.50 | 3.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $47.92 | 3.1% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $47.73 | 3.1% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $44.46 | 2.9% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $41.94 | 2.8% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $38.06 | 2.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $32.87 | 2.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.59 | 2.1% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $30.21 | 2.0% | 2 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $29.17 | 1.9% | 1 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $20.58 | 1.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.30 | 1.2% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $17.74 | 1.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.88 | 1.0% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $11.07 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,526.82 | 80 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $101.79 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $98.98 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $96.43 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $95.78 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $87.47 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $87.47 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $84.37 | 6 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $83.52 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $82.81 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $82.81 | 5 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $56.72 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $55.62 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $47.73 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $46.53 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $44.62 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $44.46 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $44.00 | 3 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $43.06 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $43.06 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $41.94 | 2 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $40.47 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $38.06 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $32.87 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $31.63 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $31.59 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.59 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $30.21 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $29.78 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $29.78 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $29.78 | 2 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $29.17 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $22.58 | 1 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $20.58 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.87 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $19.87 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $17.74 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.27 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $11.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 14 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 62 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 99 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 74 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 124 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
113 | 30 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
62 | 20 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
99 | 22 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
99 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
74 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
124 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
59 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 687 | 191 |
| Levothyroxine Sodium | Levothyroxine Sodium | 508 | 118 |
| Atorvastatin Calcium | Atorvastatin Calcium | 495 | 140 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 453 | 134 |
| Prednisone | Prednisone | 402 | 215 |
| Alprazolam | Alprazolam | 376 | 62 |
| Azithromycin | Azithromycin | 341 | 225 |
| Zolpidem Tartrate | Zolpidem Tartrate | 327 | 49 |
| Gabapentin | Gabapentin | 321 | 70 |
| Omeprazole | Omeprazole | 319 | 90 |
| Metoprolol Succinate | Metoprolol Succinate | 317 | 89 |
| Clonazepam | Clonazepam | 297 | 36 |
| Losartan Potassium | Losartan Potassium | 280 | 75 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 244 | 69 |
| Lisinopril | Lisinopril | 227 | 62 |
| Tramadol Hcl | Tramadol Hcl | 226 | 71 |
| Tizanidine Hcl | Tizanidine Hcl | 213 | 61 |
| Sertraline Hcl | Sertraline Hcl | 212 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 207 | 59 |
| Metformin Hcl | Metformin Hcl | 198 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 198 | 63 |
| Doxycycline Hyclate | Doxycycline Hyclate | 189 | 138 |
| Tamsulosin Hcl | Tamsulosin Hcl | 159 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 158 | 67 |
| Glipizide | Glipizide | 147 | 39 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 146 | 31 |
| Montelukast Sodium | Montelukast Sodium | 145 | 47 |
| Furosemide | Furosemide | 144 | 54 |
| Hydralazine Hcl | Hydralazine Hcl | 140 | 40 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 138 | 40 |
| Trazodone Hcl | Trazodone Hcl | 138 | 34 |
| Nifedipine Er | Nifedipine | 131 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 126 | 31 |
| Ozempic | Semaglutide | 124 | 25 |
| Glipizide Er | Glipizide | 122 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 122 | 37 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 119 | 31 |
| Donepezil Hcl | Donepezil Hcl | 114 | 37 |
| Synthroid | Levothyroxine Sodium | 113 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 112 | 44 |
| Meloxicam | Meloxicam | 110 | 31 |
| Carvedilol | Carvedilol | 106 | 32 |
| Januvia | Sitagliptin Phosphate | 105 | 26 |
| Jardiance | Empagliflozin | 99 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 97 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 95 | 29 |
| Lorazepam | Lorazepam | 94 | 23 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 93 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 93 | 28 |
| Famotidine | Famotidine | 90 | 31 |
| Potassium Chloride | Potassium Chloride | 88 | 30 |
| Bupropion Xl | Bupropion Hcl | 83 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 78 | 19 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 75 | suppressed |
| Mounjaro | Tirzepatide | 74 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 73 | 58 |
| Lactulose | Lactulose | 71 | 22 |
| Fenofibrate | Fenofibrate Nanocrystallized | 70 | 20 |
| Meclizine Hcl | Meclizine Hcl | 70 | 27 |
| Ondansetron Hcl | Ondansetron Hcl | 68 | 32 |
| Valacyclovir | Valacyclovir Hcl | 68 | 26 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 64 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 63 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 63 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 63 | 13 |
| Farxiga | Dapagliflozin Propanediol | 62 | 20 |
| Pregabalin | Pregabalin | 62 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 60 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 59 | 44 |
| Eliquis | Apixaban | 59 | 17 |
| Fluconazole | Fluconazole | 57 | 31 |
| Allopurinol | Allopurinol | 55 | 18 |
| Mupirocin | Mupirocin | 55 | 36 |
| Temazepam | Temazepam | 52 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 51 | 41 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 48 | 13 |
| Ezetimibe | Ezetimibe | 47 | 18 |
| Finasteride | Finasteride | 47 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 46 | 11 |
| Amoxicillin | Amoxicillin | 45 | 39 |
| Myrbetriq | Mirabegron | 45 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 44 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | 11 |
| Topiramate | Topiramate | 43 | suppressed |
| Atenolol | Atenolol | 42 | 11 |
| Celecoxib | Celecoxib | 42 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 42 | 15 |
| Mirtazapine | Mirtazapine | 41 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 41 | 11 |
| Trulicity | Dulaglutide | 41 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | suppressed |
| Colchicine | Colchicine | 38 | 18 |
| Dutasteride | Dutasteride | 38 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 38 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 35 | 11 |
| Simvastatin | Simvastatin | 35 | 11 |
| Sucralfate | Sucralfate | 34 | 12 |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Nystatin | Nystatin | 33 | 19 |
| Telmisartan | Telmisartan | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Diazepam | Diazepam | 30 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 29 | 16 |
| Ibandronate Sodium | Ibandronate Sodium | 27 | suppressed |
| Novolog Flexpen | Insulin Aspart | 27 | suppressed |
| Spironolactone | Spironolactone | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 26 | 21 |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 26 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Metronidazole | Metronidazole | 25 | 19 |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Cephalexin | Cephalexin | 22 | 20 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Cefdinir | Cefdinir | 21 | 16 |
| Ramipril | Ramipril | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 21 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 15 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Mirabegron Er | Mirabegron | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 14 | 14 |
| Glimepiride | Glimepiride | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Piroxicam | Piroxicam | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Fluocinonide | Fluocinonide | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,526.82 · 80 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AREXVY, BREZTRI, Barostim Neo System, CAPVAXIVE, CLOTTRIEVER BOLD CATHETER, COMIRNATY, CT THROMBECTOMY SYSTEM KIT, Cologuard Collection Kit, Dexcom G6 Transmitter, Dyanavel XR, FARXIGA, FLOWTRIEVER CATHETER, S, GARDASIL 9, GEMTESA, Heplisav-B, INJECTAFER, JARDIANCE, Korlym, LEQVIO, MOUNJARO, NEXPLANON, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, TZIELD, UBRELVY, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZAVZPRET | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error